FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367296890> ?p ?o ?g. }

• W4367296890 abstract "<h3>Objective:</h3> To investigate the associations among regional gray matter (GM) atrophy, neurotransmitter distributions and clinical manifestations in a large group of patients with multiple sclerosis (PwMS). <h3>Background:</h3> In multiple sclerosis (MS), clinically-relevant GM atrophy progresses in a non-random manner, possibly due to the preferential involvement of specific neurotransmitter networks, which has not been fully evaluated yet. <h3>Design/Methods:</h3> Brain 3.0 T MRI scans were acquired from 286 PwMS and 172 healthy controls (HC). Regional GM volume differences, cross-correlations between regional GM atrophy and nuclear imaging-derived neurotransmitter maps and their associations with disease duration, clinical disability, cognitive impairment, fatigue and depression were investigated using voxel-based morphometry and Juspace toolbox. <h3>Results:</h3> Compared to HC, PwMS showed a widespread cortico-subcortical GM atrophy being spatially correlated with serotonergic, dopaminergic, opioid, noradrenergic, cholinergic and glutamatergic maps (false discovery rate, [FDR]-p≤0.004). PwMS with a disease duration ≥5 vs <5 years had a significant GM atrophy in several deep GM, cortical and cerebellar regions being spatially correlated with a higher distribution of serotoninergic and dopaminergic receptors (FDR-p≤0.03). Compared to mildly-disabled PwMS, those with Expanded Disability Status Scale (EDSS)≥3.0 or ≥4.0 had significant cortical, subcortical and cerebellar atrophy, which was associated with serotonergic and dopaminergic maps (FDR-p≤0.04). A significant spatial correspondence with opioid and cholinergic maps was also found for PwMS with EDSS≥4.0 vs <4.0 (FDR-p≤0.04). Cognitively-impaired vs cognitively-preserved PwMS had a widespread GM atrophy being spatially correlated with serotonergic, dopaminergic, noradrenergic, cholinergic and glutamatergic maps (FDR-p≤0.04). PwMS with vs without fatigue had significant cortical, subcortical and cerebellar atrophy, which were associated with serotonergic, dopaminergic, opioid and glutamatergic maps (FDR-p≥0.07). No significant GM atrophy and associations with neurotransmitter maps were found according to depression. <h3>Conclusions:</h3> GM atrophy in regions belonging to specific neurotransmitter systems may contribute to explain part of MS clinical manifestations, including locomotor disability, cognitive impairment and fatigue. <b>Disclosure:</b> Mr. Preziosa has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bristol Myers Squibb . Mr. Preziosa has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi Genzyme. Mr. Preziosa has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Mr. Preziosa has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Mr. Preziosa has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck. Dr. Fiore has nothing to disclose. Dr. Tedone has nothing to disclose. Monica Margoni has received research support from MAGNIMS. Carmen Vizzino has nothing to disclose. Damiano Mistri has nothing to disclose. Dr. Gueye has nothing to disclose. Maria Assunta Rocca has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bayer, Biogen, Bristol Myers Squibb, Celgene, Genzyme, Merck Serono, Novartis, Roche, and Teva. The institution of Maria Assunta Rocca has received research support from Italian Ministry of Health, MS Society of Canada and Fondazione Italiana Sclerosi Multipla. Dr. Filippi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Bayer, Biogen Idec, Merck-Serono, Novartis, Roche, Sanofi Genzyme, Takeda, and Teva Pharmaceutical Industries. Dr. Filippi has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Bayer, Biogen Idec, Merck-Serono, Novartis, Roche, Sanofi Genzyme, Takeda, and Teva Pharmaceutical Industries. Dr. Filippi has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer Nature. The institution of Dr. Filippi has received research support from Biogen Idec, Merck-Serono, Novartis, Roche, Teva Pharmaceutical Industries, Italian Ministry of Health, Fondazione Italiana Sclerosi Multipla, and ARiSLA (Fondazione Italiana di Ricerca per la SLA)." @default.
• W4367296890 created "2023-04-29" @default.
• W4367296890 creator A5006251631 @default.
• W4367296890 creator A5014720592 @default.
• W4367296890 creator A5040220962 @default.
• W4367296890 creator A5050626771 @default.
• W4367296890 creator A5067692045 @default.
• W4367296890 creator A5068519238 @default.
• W4367296890 creator A5069531403 @default.
• W4367296890 creator A5074029422 @default.
• W4367296890 creator A5088924447 @default.
• W4367296890 date "2023-04-25" @default.
• W4367296890 modified "2023-10-16" @default.
• W4367296890 title "Correspondence Among Gray Matter Damage and Neurotransmitter Maps Is Clinically Relevant in Multiple Sclerosis (P10-3.004)" @default.
• W4367296890 doi "https://doi.org/10.1212/wnl.0000000000202276" @default.
• W4367296890 hasPublicationYear "2023" @default.
• W4367296890 type Work @default.
• W4367296890 citedByCount "0" @default.
• W4367296890 crossrefType "proceedings-article" @default.
• W4367296890 hasAuthorship W4367296890A5006251631 @default.
• W4367296890 hasAuthorship W4367296890A5014720592 @default.
• W4367296890 hasAuthorship W4367296890A5040220962 @default.
• W4367296890 hasAuthorship W4367296890A5050626771 @default.
• W4367296890 hasAuthorship W4367296890A5067692045 @default.
• W4367296890 hasAuthorship W4367296890A5068519238 @default.
• W4367296890 hasAuthorship W4367296890A5069531403 @default.
• W4367296890 hasAuthorship W4367296890A5074029422 @default.
• W4367296890 hasAuthorship W4367296890A5088924447 @default.
• W4367296890 hasConcept C118552586 @default.
• W4367296890 hasConcept C126322002 @default.
• W4367296890 hasConcept C126838900 @default.
• W4367296890 hasConcept C137183658 @default.
• W4367296890 hasConcept C142724271 @default.
• W4367296890 hasConcept C143409427 @default.
• W4367296890 hasConcept C15744967 @default.
• W4367296890 hasConcept C164705383 @default.
• W4367296890 hasConcept C169760540 @default.
• W4367296890 hasConcept C170493617 @default.
• W4367296890 hasConcept C200134340 @default.
• W4367296890 hasConcept C2775864247 @default.
• W4367296890 hasConcept C2776219046 @default.
• W4367296890 hasConcept C2778013878 @default.
• W4367296890 hasConcept C2780640218 @default.
• W4367296890 hasConcept C2780892749 @default.
• W4367296890 hasConcept C2781172350 @default.
• W4367296890 hasConcept C2781192897 @default.
• W4367296890 hasConcept C37000724 @default.
• W4367296890 hasConcept C513476851 @default.
• W4367296890 hasConcept C71924100 @default.
• W4367296890 hasConceptScore W4367296890C118552586 @default.
• W4367296890 hasConceptScore W4367296890C126322002 @default.
• W4367296890 hasConceptScore W4367296890C126838900 @default.
• W4367296890 hasConceptScore W4367296890C137183658 @default.
• W4367296890 hasConceptScore W4367296890C142724271 @default.
• W4367296890 hasConceptScore W4367296890C143409427 @default.
• W4367296890 hasConceptScore W4367296890C15744967 @default.
• W4367296890 hasConceptScore W4367296890C164705383 @default.
• W4367296890 hasConceptScore W4367296890C169760540 @default.
• W4367296890 hasConceptScore W4367296890C170493617 @default.
• W4367296890 hasConceptScore W4367296890C200134340 @default.
• W4367296890 hasConceptScore W4367296890C2775864247 @default.
• W4367296890 hasConceptScore W4367296890C2776219046 @default.
• W4367296890 hasConceptScore W4367296890C2778013878 @default.
• W4367296890 hasConceptScore W4367296890C2780640218 @default.
• W4367296890 hasConceptScore W4367296890C2780892749 @default.
• W4367296890 hasConceptScore W4367296890C2781172350 @default.
• W4367296890 hasConceptScore W4367296890C2781192897 @default.
• W4367296890 hasConceptScore W4367296890C37000724 @default.
• W4367296890 hasConceptScore W4367296890C513476851 @default.
• W4367296890 hasConceptScore W4367296890C71924100 @default.
• W4367296890 hasLocation W43672968901 @default.
• W4367296890 hasOpenAccess W4367296890 @default.
• W4367296890 hasPrimaryLocation W43672968901 @default.
• W4367296890 hasRelatedWork W1969014857 @default.
• W4367296890 hasRelatedWork W1981896177 @default.
• W4367296890 hasRelatedWork W1983138582 @default.
• W4367296890 hasRelatedWork W1990000402 @default.
• W4367296890 hasRelatedWork W2034957520 @default.
• W4367296890 hasRelatedWork W2067147530 @default.
• W4367296890 hasRelatedWork W2110176332 @default.
• W4367296890 hasRelatedWork W2278706948 @default.
• W4367296890 hasRelatedWork W2332294670 @default.
• W4367296890 hasRelatedWork W3030526960 @default.
• W4367296890 isParatext "false" @default.
• W4367296890 isRetracted "false" @default.
• W4367296890 workType "article" @default.